Brief: Aquestive Therapeutics Anticipates Increasing 2023 Revenue
09/10/2023 13:19
Oct 9 (Reuters) - Aquestive Therapeutics Inc AQST.O :
* AQUESTIVE THERAPEUTICS PROVIDES BUSINESS UPDATE
* AQUESTIVE THERAPEUTICS INC - ANTICIPATES INCREASING 2023
REVENUE
AND DECREASING NON-GAAP ADJUSTED EBITDA LOSS GUIDANCE IN
UPCOMING EARNINGS RELEASE
* AQUESTIVE THERAPEUTICS INC - REAFFIRMS Q4 2023 ANAPHYLM
PIVOTAL
PHASE 3 STUDY START AND Q1 2024 TOPLINE DATA READOUT
* AQUESTIVE THERAPEUTICS INC - INDICATES FDA REVIEW OF
LIBERVANT
(DIAZEPAM) BUCCAL FILM NDA ON TRACK WITH NO OPEN QUESTIONS
Source text for Eikon: ID:nGNXb4JnBz
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million